Literature DB >> 9260773

Sclerosing cholangitis associated with hypereosinophilic syndrome.

N Ichikawa1, A Taniguchi, H Akama, H Ishiguro, T Kurihara, C Terai, M Hara, S Kashiwazaki.   

Abstract

A 15-year-old male with hypereosinophilic syndrome was admitted to our hospital because of general malaise and abnormal liver function tests. Endoscopic retrograde cholangiopancreatography demonstrated bile duct changes consistent with primary sclerosing cholangitis. The patient's liver profile tests returned to normal after treatment with prednisolone and ursodeoxycholic acid. In this case, eosinophils might have played an important role in the pathogenesis of the bile duct lesion.

Entities:  

Mesh：

Substances：

Year:  1997        PMID： 9260773     DOI： 10.2169/internalmedicine.36.561

Source DB:  PubMed          Journal:  Intern Med        ISSN： 0918-2918            Impact factor:   1.271


  4 in total

1.  A rare manifestation of idiopathic hypereosinophilic syndrome: sclerosing cholangitis.

Authors:  Isabelle Delèvaux; Marc André; Jacques Chipponi; Anne-Marie Milési-Lecat; P Déchelotte; Olivier Aumaître
Journal:  Dig Dis Sci       Date:  2002-01       Impact factor: 3.199

2.  Clinical features of primary sclerosing cholangitis with onset age above 50 years.

Authors:  Kenji Hirano; Minoru Tada; Hiroyuki Isayama; Yoko Yashima; Hiroshi Yagioka; Takashi Sasaki; Hirofumi Kogure; Osamu Togawa; Toshihiko Arizumi; Saburo Matsubara; Yousuke Nakai; Naoki Sasahira; Takeshi Tsujino; Takao Kawabe; Masao Omata
Journal:  J Gastroenterol       Date:  2008-09-20       Impact factor: 7.527

3.  Hepatobiliary disease associated with hypereosinophilia: a report of two patients and a review of the literature.

Authors:  L M Morgan-Rowe; M Pericleous; T V Luong; J S Dooley; A K Burroughs
Journal:  Dig Dis Sci       Date:  2011-06-07       Impact factor: 3.199

Review 4.  Review of primary sclerosing cholangitis with increased IgG4 levels.

Authors:  Charis D Manganis; Roger W Chapman; Emma L Culver
Journal:  World J Gastroenterol       Date:  2020-06-21       Impact factor: 5.742
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.